xT CDx
Tempus AI, Inc. · Decision date Apr 28, 2023
What did the FDA approve?
The FDA record for P210011 lists an approval decision dated 2023-04-28 for xT CDx, a qualitative NGS-based in vitro diagnostic device. Per the source statement, it detects substitutions (SNVs and MNVs) and INDELs in 648 genes, plus microsatellite instability status, using DNA from FFPE tumor tissue and from matched normal blood or saliva, in previously diagnosed cancer patients with solid malignant neoplasms.
The stated intended uses include companion diagnostic identification of patients who may benefit from therapies listed in the Companion Diagnostic Indications table per approved therapeutic labeling, and tumor mutation profiling by qualified health care professionals per oncology professional guidelines. The statement says genomic findings outside that table are not prescriptive or conclusive for labeled use of any specific therapeutic product, and that xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL. The record carries no supplement type or reason, so the original scope is described rather than a changed item. These are reported intended uses, not independent proof of safety or clinical effectiveness.
FDA approval order statement
Approval for the xT CDx. The device is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms.The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling.Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product.xT CDx is a single-site assay performed at Tempus Labs, Inc., Chicago, IL.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Apr 28, 2023
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210011
- Regulatory pathway
- Premarket approval application
- Applicant
- Tempus AI, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Apr 28, 2023
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Tempus AI, Inc.
- Product code
- PQP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P210011 received
Application receipt date recorded by FDA.
P210011 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P210011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
xT CDxP210011/S002 | Tempus AI, Inc. | PMA supplement | Sep 2, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Tempus AI, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 600 W Chicago Ave., Suite #510, Chicago, IL, 60654
Sources and methodology
- Original FDA record: P210011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




